Dose-dependent alterations of lysosomal activity and alpha-synuclein level in peripheral blood monocyte-derived macrophages and SH-SY5Y neuroblastoma cell line by upon inhibition of mTOR kinase activity
Objective: To evaluate the perceptivity of mTOR kinase activity inhibition for Parkinson's disease therapy (PD). Background: The protein kinase mTOR is currently considered as a…Comparative-effectiveness of Foscarbidopa/foslevodopa (LDp/CDp) versus Oral Therapies in Advanced Parkinson’s Disease: A Propensity Matched Study
Objective: To assess long-term effectiveness outcomes in people with advanced Parkinson’s Disease (aPD) on LDp/CDp versus those on oral PD therapies (standard of care, SoC).…Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study.
Objective: The REONPARK study aims to evaluate COMT inhibitor (iCOMT) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s Disease patients…Pregnancy in Parkinson’s disease: Five cases
Objective: To report additional cases to the literature of Parkinson’s disease (PD) and pregnant. Background: Pregnancy in PD is a relatively rare occurrence as PD…Istradefylline therapy for dystonia in Parkinson’s disease
Objective: To clarify the basal ganglia network links between PD and Dystonia in PD (Dys-PD) co-occur, and to get the conceptually novel pharmacotherapy. Background: Dys-PD is one…Neuronal Exosome based markers in Parkinson’s Disease and Progressive Supranuclear Palsy
Objective: This study aimed to explore cellular inflammatory and autophagic mediators in neuronal exosomes of PD and PSP. Background: Parkinson’s disease (PD) is a common…LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Pathologic Alpha-Synuclein: Clinical and Biomarker Characterization
Objective: To compare clinical and biomarker features and rate of progression among LRRK2-associated parkinsonism cases with and without in vivo evidence of pathologic alpha-synuclein (asyn)…Functionality Analysis of Immunoregulatory Cells Stimulated with Dopaminergic Agonists in People Living with Parkinson’s Disease
Objective: To evaluate the effect of dopaminergic agonists (DA) on the activation and functionality of regulatory cells in People living with Parkinson's Disease (PwP). Background:…Early GBA-Related Parkinson’s Disease has a Distinct Clinical Phenotype and Cholinergic Innervation
Objective: This study aims to characterize the clinical features and cholinergic innervation of early Parkinson’s disease (PD) patients with GBA mutations (GBA-PD). Background: The GBA-PD…Synaptic Density Loss in Parkinson’s Disease Independent of Age: Preliminary Findings using [18F]SynVesT-1 PET Tracer
Objective: To determine whether synaptic density differs in the brain of people with Parkinson’s disease and healthy controls using the [18F]-SynVesT-1 PET tracer. Background: The…
- « Previous Page
- 1
- …
- 117
- 118
- 119
- 120
- 121
- …
- 436
- Next Page »